ClinicalTrials.Veeva

Find clinical trials for Kidney Disease in London, England

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Kidney Diseases
Chronic Renal Insufficiency
Chronic Kidney Failure
Renal Insufficiency
IGA Glomerulonephritis
Renal Cell Carcinoma
Diabetes Mellitus

Kidney Disease trials near London, England, GBR:

A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

is to evaluate the effect of tolvaptan on the need for renal replacement therapy in pediatric subjects with autosomal recessive polycystic kidney...

Enrolling
Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Drug: Tolvaptan (OPC-41061)

Phase 3

Otsuka
Otsuka

London, United Kingdom and 17 other locations

The purpose of this study is to access the efficacy and safety of MC2-25 cream and MC2-25 vehicle for treatment of chronic kidney disease...

Enrolling
Chronic Kidney Disease-associated Pruritus
Drug: MC2-25 cream
Drug: MC2-25 vehicle

Phase 2

MC2 Therapeutics

London, United Kingdom

to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney...

Enrolling
Chronic Kidney Disease With High Proteinuria
Drug: Zibotentan/Dapagliflozin
Drug: Dapagliflozin

Phase 3

AstraZeneca
AstraZeneca

London, United Kingdom and 305 other locations

of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys...

Active, not recruiting
Chronic Kidney Diseases
Type 2 Diabetes Mellitus
Biological: Renal Autologous Cell Therapy (REACT)

Phase 3

Prokidney

London, United Kingdom and 45 other locations

tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney...

Enrolling
Proteinuric Kidney Disease
Drug: VX-147
Drug: Placebo

Phase 2, Phase 3

Vertex Pharmaceuticals
Vertex Pharmaceuticals

London, United Kingdom and 231 other locations

The primary objective of this study is to evaluate the safety of tolvaptan in pediatric subjects with autosomal recessive polycystic kidney ...

Enrolling
Autosomal Recessive Polycystic Kidney (ARPKD)
Drug: Tolvaptan Suspension
Drug: Tolvaptan Tablets

Phase 3

Otsuka
Otsuka

London, United Kingdom and 18 other locations

Researchers are looking for a better way to treat people who have non-diabetic chronic kidney disease (non-diabetic CKD). The trial ...

Active, not recruiting
Non-diabetic Chronic Kidney Disease
Drug: Finerenone (BAY94-8862)
Drug: Placebo

Phase 3

Bayer
Bayer

London, United Kingdom and 312 other locations

Researchers are looking for a better way to treat people with chronic kidney disease (CKD), a progressive decrease in the kidneys...

Enrolling
Chronic Kidney Disease
Type 1 Diabetes Mellitus
Other: Placebo
Drug: Finerenone

Phase 3

Bayer
Bayer

London, United Kingdom and 80 other locations

The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the cl...

Enrolling
Chronic Kidney Disease
Cardiac Disease
Drug: Placebo
Drug: Ravulizumab

Phase 3

Alexion Pharmaceuticals
Alexion Pharmaceuticals

London, United Kingdom and 159 other locations

Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney...

Enrolling
Chronic Kidney Disease
Proteinuria
Drug: Finerenone (Kerendia, BAY94-8862)

Phase 3

Bayer
Bayer

London, United Kingdom and 141 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems